Evamed showcases comprehensive clinical support for medical device manufacturers at EUCROF24 

February 20 2024

Evamed, a leading French clinical research company specialising in the evaluation and clinical investigation of medical devices – and part of the esteemed 1MED Group – is pleased to announce its participation at EUCROF24.

At EUCROF 2024, Evamed will showcase its expertise in post-marketing support for medical device manufacturers, enhanced by the pre-marketing and clinical services provided by 1MED Group’s experts. This collaboration underscores Evamed’s commitment to providing comprehensive solutions for medical device companies throughout the product lifecycle.

Founded in 2005, Evamed has established itself as a trusted partner for clinical study projects, offering global management services for all types of medical devices, from class I to class III, across various therapeutic fields. With a focus on higher risk devices, Evamed’s team of experts ensures efficient regulatory approval and rapid market access for manufacturers. One of their key offerings is to help manufactures gather real-life clinical data, ensuring the efficacy and safety of medical devices post-market release.

1MED-SA is renowned for its leadership on providing in depth end-to-end development expertise within the medical device, novel technology and combination products field across the European market. By offering a comprehensive range of services tailored to gather relevant data and evidence, 1MED assists manufacturers in demonstrating the safety and effectiveness of their products.

The acquisition of Evamed by 1MED in September 2023 further solidified 1MED’s presence in Europe, particularly in France, a key European market, and bolstered the company’s capabilities in conducting high-complexity international trials. Evamed’s customers now benefit from access to a larger platform and a broader network of partners, along with 1MED’s high-quality specialist services.

Evamed’s participation at EUCROF24 marks the first time it will be exhibiting under the banner of 1MED Group, offering manufacturers a one-stop solution to address the multifaceted challenges associated with bringing innovative products to market.

Vincenzo Lopreiato, Chief Commercial Officer of 1MED SA, said: “Our collaboration represents a unique opportunity for medical device companies to access a comprehensive suite of services that seamlessly integrate post-market clinical support with pre-marketing and clinical services. By leveraging Evamed’s established reputation and extensive experience in clinical study management, coupled with 1MED Group’s medical devices specialised knowledge, manufacturers can benefit from a tailored approach aimed at expediting regulatory approval processes and facilitating rapid market access.”

Evamed’s presence at EUCROF24 highlights the importance of updating clinical data through post-marketing monitoring studies, which have become standard in the medical device lifecycle. With extensive experience in end-to-end development solutions for medical devices, in vitro diagnostics, and combination products, Evamed is uniquely positioned to support manufacturers in navigating complex regulatory landscapes and achieving successful project outcomes.

EUCROF24 is a premier platform for industry stakeholders, including pharma, biotech, medical device companies, CROs, regulators, patients, and academia, to discuss current challenges and future directions in clinical research across Europe.

For more information about EUCROF24, please visit: https://conference.eucrof.eu/

If you’re heading to EUCROF24, be sure to swing by Stand #24. Let’s chat about how we can support your journey in bringing innovative medical devices to life!